Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Dendreon gets a nice boost.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Alert: Top Cash Back Card Now Offers 0% Intro APR Until Nearly 2027
Enjoy 0% intro APR on purchases and balance transfers for 15 months—plus up to 5% cash back in popular categories.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-28 21:20:18.243176.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
In the following video, Motley Fool health-care analyst David Williamson discusses Dendreon's (NASDAQ: DNDN) strong quarterly results that included top-line growth. Dendreon announced preliminary results in early January, so many of the numbers weren't big news, but David takes investors through key takeaways from the conference call, including progress on Dendreon's restructuring, its surprising forecast for the current quarter, and why management thinks the future is bright.